Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Am J Transplant. 2023 Jan 19;23(4):559–564. doi: 10.1016/j.ajt.2022.12.019

Table 2:

dnDSA Characteristics of Study Population

Characteristics dnDSA+ (n=145) Early Treatment (n=30) No Early Treatment (n=115)

Median days to dnDSA 38 11 75

HLA Class I 12 (8%) 3 (10%) 9 (8%)

HLA Class II 110 (76%) 16 (53%) 94 (81%)
 DQ 89 (61%) 13 (43%) 76 (66%)
 DP/DR 12 (8%) 3 (10%) 9 (8%)
 DQ + DP/DR 9 (8%) 0 9 (8%)

HLA Class I and II 17 (12%) 6 (20%) 11 (10%)

Other Combinations 6 (4%) 5 (17%) 1 (1%)